Clovis Oncology

^{, Nasdaq: CLVS}

Biotech formed by Pharmion execs to develop pancreas and lung cancer drugs.

Industry: Health Care

First Day Return: -3.4%

CLVS

Biotech formed by Pharmion execs to develop pancreas and lung cancer drugs.

IPO News for Clovis Oncology

Clovis Oncology quiet period ends December 26 12/21/11
Clovis Oncology prices IPO at $13, at low end of the range 11/15/11
9 IPOs planned for the week of Nov 14 11/14/11

IPO Data
IPO Date	11/15/2011
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$130
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.clovisoncology.com
Headquarters	Boulder, CO, United States
Founded	2009
Employees at IPO	45

IPO News for Clovis Oncology

Clovis Oncology quiet period ends December 26 12/21/11
Clovis Oncology prices IPO at $13, at low end of the range 11/15/11
9 IPOs planned for the week of Nov 14 11/14/11

Clovis Oncology (CLVS) Performance